Definium Therapeutics to Discuss Phase 3 Panorama Results for Lysergide ODT in Generalized Anxiety Disorder on September 14, 2026

Definium Therapeutics announced a webcast to discuss topline results from Panorama, its second Phase 3 study of DT120, a lysergide orally disintegrating tablet, in adults with generalized anxiety disorder. The randomized, double-blind, placebo-controlled trial enrolled 245 participants aged 18 to 74 across approximately 32 centers. Participants received a single 100 microgram or 50 microgram DT120 dose, or placebo, followed by a 12-week blinded treatment period and a 40-week open-label extension that could include up to four additional 100 microgram doses. The primary endpoint is change in HAM-A anxiety scores at Week 12, with CGI-S and earlier HAM-A and CGI-S measures as key secondary endpoints. The webcast was scheduled for September 14, 2026, at 8:00 a.m. EDT. The release provides no efficacy or safety results and emphasizes that plans and potential benefits remain forward-looking statements subject to clinical, regulatory, financing, and controlled-substance risks.